ZYBERNO
Stock Report
Updated Aug 31, 2026

Voyager Therapeutics, Inc. (VYGR)

Healthcare • NASDAQ

$3.54

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
30.0/100
WEAK BUSINESS
Voyager Therapeutics, Inc. (VYGR) scores 30/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-57.9%)
Debt-to-Equity (Solvency Risk):GOOD (0.42x)
Operating Margin (Operational Efficiency):CRITICAL (-340.1%)
Return on Capital (Capital Efficiency):CRITICAL (-230.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Voyager Therapeutics, Inc. (VYGR) stock report — Zyberno Score 30/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VYGR generated -$129.90M in Owner Earnings. Capital was deployed as follows: $1.95M invested in capital expenditures. Reinvestment rate: 1.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.54
Market Cap:$214.34M

Valuation Multiples (3)

P/B Ratio:1.39x
P/S Ratio:6.22x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$98.11M

Price Action & Momentum (3)

Momentum Percentile:57 / 100
% of 52-Week High:63.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-45.0%
Reinvestment Rate:1.7%
Fundamental Growth Rate (g):-3.8%

Margin Analysis (3)

Operating Margin Ttm:-340.1%
Net Margin Ttm:-312.6%
Ebitda Margin:-328.5%

TTM Performance (2)

Operating Margin Ttm:-340.1%
Net Margin Ttm:-312.6%

Yield Metrics (2)

Earnings Yield:-$55.35
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:24.3%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):65.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.51x
Quick Ratio:7.51x
Cash Ratio:8.92x

Leverage Analysis (3)

Debt To Equity Ttm:0.42x
Debt-to-Equity Ratio:0.42x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:108,543,000.00
Cash And Cash Equivalents:148,800,000.00
Long Term Debt:$25.69M
Net Debt:-$116.23M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $34.46M
Linear Growth: 65.2%
📊 Click to view full VYGR Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$117.19M

Bottom Line Performance (3)

-$107.73M
Income Before Tax:-$107.60M
Ebitda Ttm:-113,210,000.00

Operating Expenses (5)

Operating Expenses:151,647,000.00
R And D Expense:118,461,000.00
Sga Expense:33,186,000.00
Income Tax Expense:$126.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:3,742.8%
Sga To Revenue Percentage:1,048.5%
Ebitda Margin:-328.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$197.75M
Current Assets:$125.23M
Ppe Net:11,194,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:43,376,000.00
Current Liabilities:16,685,000.00
Long Term Debt:$25.69M
Short Term Debt:$6.88M

Equity & Capital (3)

Equity:$154.38M
Retained Earnings:-$498.32M
Common Stock:240,000,000.00

Working Capital Items (3)

Accounts Receivable:2,932,000.00
Inventory:0.00
Accounts Payable:7,951,000.00

Special Items (2)

Contract Liabilities:244,000.00
Stock Based Compensation:2,433,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$127.99M-$129.94M

Investment Activities (2)

Investing Cash Flow:$8.10M
Capital Expenditures Ttm:1,952,000.00

Financing Activities (3)

Financing Cash Flow:$3.33M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,038,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:3,978,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.81
-$1.81
Earnings Per Share Ttm:-$1.78

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.57
Operating Cash Flow Per Share:-$2.19

Book Value & Capital (2)

Book Value Per Share:$2.55
Cash Per Share:2.46

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.14x
Working Capital Turnover Ttm:0.32x

Receivables Management (2)

Receivables Turnover Ttm:11.75x
Days Sales Outstanding Ttm:31.06

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:84.22
Cash Conversion Cycle:-1,052.16
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$129.90M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.7%
Fundamental Growth Rate (g):-3.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):65.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):24.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:VYGR
Company Name:Voyager Therapeutics, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:60.55M
Shares Outstanding Basic:60.55M
Shares Outstanding Diluted:60.55M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 08:02:16 UTC
Data Timestamp:2026-08-18T20:58:34.687964
Scroll to Top